Latest Insights - page 28 | BiopharmaTrend

Sofinnova's Startups Get NVIDIA GPU Access to Accelerate Biological AI Models

Sofinnova Partners has announced a collaboration with NVIDIA to provide high-performance AI computing infrastructure to select companies in its life sciences portfolio. Through access to NVIDIA DGX Cloud Lepton, participating …

Continue ›››

Insilico Medicine Launches its Multimodal Generative Chemistry Model on AWS Marketplace

Insilico Medicine has released Nach01, a large-scale generative chemistry foundation model, on the AWS Marketplace. The model combines structural and spatial representation learning and is built to handle hundreds of …

Continue ›››

MIT and Recursion Launch Boltz-2, Open-Source AI Foundation Model for Structure and Binding Affinity Prediction

Researchers at MIT’s Jameel Clinic and CSAIL, in collaboration with Recursion and leveraging NVIDIA’s BioHive-2 supercomputer, have released Boltz-2, an open-source biomolecular foundation model designed to simultaneously predict 3D protein …

Continue ›››

17 More Biomedical Foundation Models

MIT & Recursion's Boltz-2 just launched—here’s a quick scan of 15+ new models spanning chemistry, oncology, trials, and clinical workflows The latest addition arrived yesterday: Boltz-2, an open-source model from MIT …

Continue ›››

FutureHouse Debuts Scientific Reasoning LLM Model Trained for Chemistry

FutureHouse has released ether0, a 24B-parameter open-weight language model specialized for chemistry tasks. Built on Mistral 24B Instruct and refined through reinforcement learning, the model is designed for molecular generation …

Continue ›››

The Stage Is Set: London Biotechnology Show 2025

The inaugural London Biotechnology Show (LBS 2024) took place on 8–9 May 2024 at Olympia West, London, and culminated in an insightful discussion of emerging disruptive technologies such as AI …

Continue ›››

Kiin Bio Raises $2.2M Pre-Seed to Build AI Platform of "Virtual Scientists" for Drug Discovery

Kiin Bio, a 2024-founded startup developing an AI-native research platform for drug discovery, has raised $2.2 million in pre-seed funding led by b2venture. The company’s platform deploys “Virtual Scientists”—generative AI …

Continue ›››

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

In this report: Intro: The New Framework “AI Drug Discovery” is About Holism "AI Drug Discovery" is About Building Software Access to Data is King Validation is Critical for AI …

Continue ›››

FDA Launches Internal AI Tool "Elsa" to Streamline Regulatory and Scientific Workflows

The U.S. Food and Drug Administration has deployed Elsa, an internal generative AI tool designed to assist employees with tasks such as protocol reviews, adverse event summarization, label comparisons, and …

Continue ›››

Sarepta Secures First FDA Platform Designation for Gene Therapy Delivery Technology

The U.S. FDA has granted Platform Technology Designation to Sarepta Therapeutics’ rAAVrh74 viral vector, the delivery component used in SRP-9003, an investigational gene therapy for limb-girdle muscular dystrophy type 2E/R4 …

Continue ›››

ImmunoPrecise AI Discovers Pan-Serotype Dengue Vaccine Target Fully In Silico

ImmunoPrecise Antibodies Ltd. (IPA) reported an in silico discovery of a single, strictly conserved epitope across all four dengue virus serotypes using its LENSai platform and patented HYFT technology. The …

Continue ›››

Antheia Raises $56M Series C to Scale Biosynthetic Drug Ingredient Production, Expands to Asia

Menlo Park–based biomanufacturing company Antheia, founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, announced a $56 million Series C funding round led by Global Health Investment Corporation …

Continue ›››